Cancer Biopsy Market Worth US$ 66.1 Billion, Globally, by 2030

The global cancer biopsy market is projected to grow from USD 25.54 billion in 2021 and is projected to reach USD 66.1 billion by 2030; it is expected to grow at a CAGR of 17.6 % from 2022 to 2030. The report contains 150+ pages with detailed analysis.

The base year for the study has been considered 2021, the historic year 2017 and 2020, the forecast period considered is from 2022 to 2030. The cancer biopsy market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).

The most common way for doctors to diagnose cancer is through a biopsy. Other tests can indicate the presence of cancer, but only a biopsy can confirm the diagnosis. A biopsy is a procedure in which a doctor takes a small piece of tissue for examination under a microscope. However, obtaining a tissue sample may necessitate surgery or another operation. The sort of biopsy one undergoes is determined by the location of the suspected tumor. The rising incidence and prevalence of cancer, as well as the growing desire for non-invasive treatment approaches, are driving the growth of the cancer biopsy market during the forecast period.

Download the FREE Sample Report (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1514

The results of biopsy can be used by doctors to decide a patient’s treatment plan. These benefits are bolstering vendors’ efforts to provide patients with lung cancer with a customized treatment plan. The personalized medicine ensures that medications are targeted and actionable. During the forecast period, one of the important aspects likely to have favorable impact on the cancer biopsy market is the use of liquid biopsy for personalized treatment. However, due to tissue biopsy constraints, cancer misdiagnosis, delayed diagnosis, and insufficient tumor sampling are all common.

Scope of the Cancer Biopsy Market

Report Highlights

• Based on the type, the tissue biopsy segment dominated the global cancer biopsy market in 2020 with highest market share. Tissue biopsies are commonly used to diagnose cancer, but they can also be used to diagnosis infections, autoimmune illnesses, and inflammatory diseases.
• Kits and consumables accounted for the biggest revenue share by product in 2020. Due to the considerable movement from tumor to liquid biopsy, the use of kits and consumables is projected to expand at rapid pace.
• Breast cancer dominated the global cancer biopsy market in terms of application in 2020, and it is expected to continue to do so throughout the forecast period. A reference standard for the examination of patients with a suspicious breast lesion is an open surgical biopsy.

Market Dynamics

Drivers

Increasing significance of companion diagnostics

The companion diagnostics are tests that help doctors make treatment decisions for patients based on their response to therapy. The foundation of companion diagnostics with therapeutic goods has the potential to radically modify the drug development process and commercialize drug candidates by swiftly and cost-effectively delivering safer medications with improved therapeutic efficacy. The market for companion diagnostics has a lot of growth opportunities because of the rising need for high priced specialist therapies and safer medications. Thus, the increasing significance of companion diagnosis is propelling the growth of the global cancer biopsy market during the forecast period.

Restraints

Unclear reimbursement scenarios

The process of paying for expensive molecular testing, as well as the expertise of the various professionals needed to interpret test results and establish treatment programs, is inefficient and complicated. This is especially true in the case of emerging technologies with bigger price tags, such as liquid biopsy. Thus, this factor is restricting the market growth.

Opportunities

Rising prevalence of various cancers

There has been a huge increase in the number of people diagnosed with cancer around the world. The environmental causes, infectious agents such as Hepatitis B and C, cigarette consumption, and lifestyle changes are all contributing to the increased cancer prevalence. The reduced cost, therapy monitoring, early prognosis, detection of tumor heterogeneity, patient comfort, and acquired drug resistance are all advantages of biopsy over standard cancer diagnostics approaches. As a result, the rising prevalence of various types of cancers is creating lucrative opportunities for the growth of the global cancer biopsy market during the forecast period.

Challenges

Limitations to the biopsy process

The amount of tissue retrieved from a needle biopsy may not be sufficient in some situations, and the biopsy may need to be repeated. Less invasive breast biopsy methods may occasionally fail to detect lesions or determine the extent of illness. The surgical biopsy is frequently required if the diagnosis remains questionable following a technically effective treatment. Thus, the limitations of the biopsy process are creating obstacles for the growth of the cancer biopsy market.

Regional Snapshot

North America is the largest segment for cancer biopsy market in terms of region. The wide availability of technologically advanced instruments, highly developed healthcare systems in the U.S. and Canada, and the existence of numerous prominent national clinical laboratories account for the considerable proportion of this regional segment.

Asia-Pacific region is the fastest growing region in the cancer biopsy market. The regional expansion will be aided by increased cancer incidence, faster adoption of advanced methods, and highly upgraded infrastructure. The segment will also see exceptional development potential as the need for non-invasive illness detection grows, and the key market players continue to launch new products with a strong focus on research and development.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers, novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the major players in the global cancer biopsy market include:

• Myriad Genetics Inc.
• Guardant Health Inc.
• Exact Sciences Corporation
• Bio-Rad Laboratories Inc.
• Agena Bioscience Inc.
• Personal Genome Diagnostics Inc.
• Exosome Diagnostics Inc.
• ANGLE Plc.
• F. Hoffmann-La Roche Ltd.

Segments Covered in the Report

By Product

• Instruments
• Kits and Consumables
• Services

By Type

• Tissue Biopsies
  • Fine Needle Aspiration (FNA)
  • Core Needle Biopsy (CNB)
  • Needle Biopsies
  • Surgical Biopsies
• Liquid Biopsies
• Others

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Biopsy Market 

5.1. COVID-19 Landscape: Cancer Biopsy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Biopsy Market, By Product

8.1. Cancer Biopsy Market, by Product Type, 2021-2030

8.1.1. Instruments

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Kits and Consumables

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Services

8.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Cancer Biopsy Market, By Application

9.1. Cancer Biopsy Market, by Application, 2021-2030

9.1.1. Breast Cancer

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Colorectal Cancer

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cervical Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Lung Cancer

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Prostate Cancer

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Skin Cancer

9.1.6.1. Market Revenue and Forecast (2019-2030)

9.1.7. Blood Cancer

9.1.7.1. Market Revenue and Forecast (2019-2030)

9.1.8. Kidney Cancer

9.1.8.1. Market Revenue and Forecast (2019-2030)

9.1.9. Liver Cancer

9.1.9.1. Market Revenue and Forecast (2019-2030)

9.1.10. Pancreatic Cancer

9.1.10.1. Market Revenue and Forecast (2019-2030)

9.1.11. Ovarian Cancer

9.1.11.1. Market Revenue and Forecast (2019-2030)

9.1.12. Others

9.1.12.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Cancer Biopsy Market, By Type 

10.1. Cancer Biopsy Market, by Type, 2021-2030

10.1.1. Tissue Biopsies (Fine Needle Aspiration (FNA), Core Needle Biopsy (CNB))

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Liquid Biopsies

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Cancer Biopsy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by Type (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Type (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by Type (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Type (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Type (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Type (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by Type (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Type (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Type (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Type (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Type (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Type (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Type (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by Type (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Type (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Type (2019-2030)

Chapter 12. Company Profiles

12.1. Myriad Genetics Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Guardant Health Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Exact Sciences Corporation

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Bio-Rad Laboratories Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Agena Bioscience Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Personal Genome Diagnostics Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Exosome Diagnostics Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. ANGLE Plc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. F. Hoffmann-La Roche Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Why Buy this Report?

The purpose of Precedence Research’s cancer biopsy market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1514

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com